Form 4 for IONS IONIS PHARMACEUTICALS INC
Accepted 2023-12-28 00:00:00 ET · period of report 2023-12-26 · accession 0000874015-23-000241 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-12-28 | 2023-12-26+ | IONS | PARSHALL B LYNNE | Dir | S - Sale+OE | $50.48 | -117.6K | 82.6K | -59% | -$5.94M |
| DM | 2023-12-28 | 2023-12-26+ | IONS | PARSHALL B LYNNE | Dir | M - OptEx | $47.34 | +117.6K | 125.1K | +1,574% | +$5.57M |
| DM | 2023-12-28 | 2023-12-26+ | IONS | PARSHALL B LYNNE | Dir | M - OptEx | $0.00 | -117.6K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-26 | S | D | 25,113 | $51.46 | 82,588 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.30 to $51.60 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) on this Form 4. |
| 2 | Common | Common Stock | 2023-12-26 | M | A | 25,113 | $47.34 | 107,701 | D | — | — | |
| 3 | Common | Common Stock | 2023-12-27 | M | A | 50,000 | $47.34 | 132,588 | D | — | — | |
| 4 | Common | Common Stock | 2023-12-28 | M | A | 42,525 | $47.34 | 125,113 | D | — | — | |
| 5 | Common | Common Stock | 2023-12-28 | S | D | 42,525 | $50.19 | 82,588 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.75 to $50.50 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. |
| 6 | Common | Common Stock | 2023-12-27 | S | D | 50,000 | $50.23 | 82,588 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.07 to $50.75 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. |
| 7 | Derivative | Non-Qualified Stock Option (right to buy) | 2023-12-26 | M | D | 25,113 | $0.00 | 92,525 | D | $47.34 · 2019-01-03 to 2024-01-02 | 25,113 Common Stock | |
| 8 | Derivative | Non-Qualified Stock Option (right to buy) | 2023-12-27 | M | D | 50,000 | $0.00 | 42,525 | D | $47.34 · 2020-01-03 to 2024-01-02 | 50,000 Common Stock | |
| 9 | Derivative | Non-Qualified Stock Option (right to buy) | 2023-12-28 | M | D | 42,525 | $0.00 | 0 | D | $47.34 · 2021-01-03 to 2024-01-02 | 42,525 Common Stock |